Key clinical point: Hu5F9-G4 plus rituximab was safe and produced durable complete responses in patients with relapsed or refractory non-Hodgkin lymphoma.
Major finding: Rates of overall and complete responses were 50% and 36%, respectively, with most responses ongoing at the time of data cutoff.
Study details: A phase 1b study of 22 patients, including 15 with diffuse large B-cell lymphoma and 7 with follicular lymphoma.
Disclosures: The study was supported by Forty Seven and the Leukemia & Lymphoma Society. Study authors reported disclosures related to Forty Seven, Bristol-Myers Squibb, Pharmacyclics, Seattle Genetics, and Roche/Genentech, among others.
Advani R et al. N Engl J Med. 2018;379:1711-21.
This Week's Must Reads
BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia, Leukemia & Lymphoma 2018
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.
Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018
Must Reads in Aggressive Lymphomas
Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8
5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21
Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025
Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014
Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85